aTyr Pharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $50.9M
- Price
- $0.503
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.22%
- Volume
- 679.2K
About
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Quick stats
Shares outstanding98.1M
Computed float95.6M
Float / shares97.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001339970
Websitehttps://www.atyrpharma.com
AI Summary
AI-generated1/8
majorneutralrestructuring
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma announced a corporate restructuring featuring a 60% workforce reduction and program prioritization to conserve capital, expected to reduce annualized operating expenses by approximately $13 million starting in the fourth quarter of 2026.
The company reported $58.9 million in cash and investments as of June 30, 2026, providing a runway into late 2028 based on current operations, though it noted that the planned Phase 3 study will require additional capital raising.
Operational updates include the completion of enrollment in the Phase 2 EFZO-CONNECT study with topline data expected in Q1 2027, and the expectation of FDA feedback on a Phase 3 protocol by the end of August 2026.
Red flags
- Workforce reduction of 60% indicates severe operational retrenchment
- CFO and General Counsel stepping down
- Future Phase 3 development funding dependent on additional capital raises